Get started
Author

Sharada Kolekar

Observed names: Kolekar, Sharada, S Kolekar, S. Kolekar, Sharada V. Kolekar
ORCID: 0000-0003-1765-7378
Observed ORCID: 0000-0003-1765-7378
OpenAlex ID: A5084470237
A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types
2011 · Stephen Jamieson, Jack U. Flanagan, et al. · Biochemical Journal · 165
A core outcome set for future endometriosis research: an international consensus development study
2020 · JMN Duffy, M Hirsch, et al. · BJOG An International Journal of Obstetrics & Gynaecology · 119
PDF
Synthesis and Biological Evaluation of Novel Analogues of the Pan Class I Phosphatidylinositol 3-Kinase (PI3K) Inhibitor 2-(Difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1 H -benzimidazole (ZSTK474)
2011 · Gordon W. Rewcastle, Swarna A. Gamage, et al. · Journal of Medicinal Chemistry · 107
Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth
2015 · Melanie Sweetlove, Emma Wrightson, et al. · Frontiers in Oncology · 71
PDF
Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
2021 · Khanh B. Tran, Sharada Kolekar, et al. · BMC Cancer · 36
PDF
Novel pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors: Exploring the benzenesulfonohydrazide SAR
2011 · Jackie D. Kendall, Anna C. Giddens, et al. · Bioorganic & Medicinal Chemistry · 36
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors
2011 · Jackie D. Kendall, Patrick D. O’Connor, et al. · Bioorganic & Medicinal Chemistry · 31
Synthesis and biological evaluation of novel phosphatidylinositol 3-kinase inhibitors: Solubilized 4-substituted benzimidazole analogs of 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474)
2013 · Gordon W. Rewcastle, Swarna A. Gamage, et al. · European Journal of Medicinal Chemistry · 22
Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
2017 · Gordon W. Rewcastle, Sharada Kolekar, et al. · Oncotarget · 16
PDF
Exploring the isoform selectivity of TGX-221 related pyrido[1,2-a]pyrimidinone-based Class IA PI 3-kinase inhibitors: Synthesis, biological evaluation and molecular modelling
2015 · Andrew J. Marshall, Claire L. Lill, et al. · Bioorganic & Medicinal Chemistry · 16
Novel pyrazolo[1,5-a]pyridines as PI3K inhibitors: variation of the central linker group
2013 · Jackie D. Kendall, Andrew J. Marshall, et al. · MedChemComm · 15
A second-generation molecular clamp stabilised bivalent candidate vaccine for protection against diseases caused by respiratory syncytial virus and human metapneumovirus
2025 · Andrew Young, Sharada Kolekar, et al. · PLoS Pathogens · 13
PDF
Genomic and signalling pathway characterization of the NZM panel of melanoma cell lines: A valuable model for studying the impact of genetic diversity in melanoma
2020 · Khanh B. Tran, Gregory Gimenez, et al. · Pigment Cell & Melanoma Research · 13
PDF
Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
2022 · Khanh B. Tran, Sharada Kolekar, et al. · Molecular Cancer Therapeutics · 10
Novel pyrazolo[1,5-a]pyridines with improved aqueous solubility as p110α-selective PI3 kinase inhibitors
2016 · Jackie D. Kendall, Anna C. Giddens, et al. · Bioorganic & Medicinal Chemistry Letters · 10
412P Effects of statins on melanoma
2016 · K.B. Tran, S. Kolekar, et al. · Annals of Oncology · 1
Supplementary Data from Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
2023 · Khanh B. Tran, Sharada Kolekar, et al.
Data from Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
2023 · Khanh B. Tran, Sharada Kolekar, et al.
Data from Response to BRAF-targeted Therapy Is Enhanced by Cotargeting VEGFRs or WNT/β-Catenin Signaling in BRAF-mutant Colorectal Cancer Models
2023 · Khanh B. Tran, Sharada Kolekar, et al.
Additional file 7 of Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
2021 · Tran, Khanh B., Kolekar, Sharada, et al. · Figshare
Additional file 1 of Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
2021 · Tran, Khanh B., Kolekar, Sharada, et al. · Figshare
Additional file 5 of Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
2021 · Tran, Khanh B., Kolekar, Sharada, et al. · Figshare
Additional file 6 of Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
2021 · Tran, Khanh B., Kolekar, Sharada, et al. · Figshare
Additional file 8 of Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
2021 · Tran, Khanh B., Kolekar, Sharada, et al. · Figshare
Additional file 4 of Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
2021 · Tran, Khanh B., Kolekar, Sharada, et al. · Figshare
Works count: 37
Citation count: 681
H-index: 13
I10-index: 15
Year
Topic
Type